Soligenix, Inc. (NASDAQ:SNGX) Director Mark E. Pearson bought 170,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 17th. The shares were acquired at an average cost of $1.16 per share, for a total transaction of $197,200.00. Following the purchase, the director now directly owns 2,500,000 shares in the company, valued at approximately $2,900,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
NASDAQ:SNGX opened at $1.08 on Thursday. Soligenix, Inc. has a 1 year low of $0.91 and a 1 year high of $3.70.
Soligenix (NASDAQ:SNGX) last released its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.06). Soligenix had a negative return on equity of 176.04% and a negative net margin of 120.14%. The firm had revenue of $1.70 million during the quarter, compared to the consensus estimate of $1.20 million. On average, sell-side analysts predict that Soligenix, Inc. will post -0.68 EPS for the current year.
Soligenix Company Profile
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.
Read More: What are the most popular ETFs
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.